|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness.
|
16564107 |
2006 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness.
|
16564107 |
2006 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Expression of aspartyl beta-hydroxylase and its clinicopathological significance in hepatocellular carcinoma.
|
16341145 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Western blot analysis detected the approximately 86 kDa AAH protein in all five cholangiocarcinoma cell lines, and higher levels of AAH in cell lines derived from moderately or poorly differentiated compared with well-differentiated tumors.
|
12713872 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A modest but significant effect on tumor growth was observed in animals treated with an antisense ON directed against both BAH and humbug transcripts.
|
12130746 |
2002 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Aspartyl (asparaginyl) beta-hydroxylase (AAH) is overexpressed in various malignant neoplasms, and high levels of immunoreactivity mainly occur in infiltrating or metastasized tumors.
|
12118090 |
2002 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We previously reported overexpression of the HAAH gene in human hepatocellular carcinomas and cholangiocarcinomas (L. Lavaissiere et al., J. Clin.Investig., 98: 1313-1323, 1996).
|
10728685 |
2000 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma.
|
8823296 |
1996 |
|
Malocclusion
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Convex nasal ridge
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Downward slant of palpebral fissure
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Atrophic iris
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Dysmorphic facies
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Large nose
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Retrognathia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Large beaked nose
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Cholangiocarcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation.
|
29733964 |
2018 |
|
Cholangiocarcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Immunization with ASPH-loaded DCs generated cytotoxicity against cholangiocarcinoma cells in vitro and significantly suppressed intrahepatic tumor growth and metastasis, and was associated with increased CD3+ lymphocyte infiltration into the tumors.
|
21898484 |
2012 |
|
Cholangiocarcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Detection of human aspartyl (asparaginyl) beta-hydroxylase and homeobox B7 mRNA in brush cytology specimens from patients with bile duct cancer.
|
16673309 |
2006 |
|
Cholangiocarcinoma
|
0.060 |
AlteredExpression
|
disease |
LHGDN |
Correspondingly, antisense and not sense or mutated antisense AAH oligodeoxynucleotides significantly inhibited AAH expression and motility in cholangiocarcinoma cells.
|
12713872 |
2003 |
|
Cholangiocarcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Correspondingly, antisense and not sense or mutated antisense AAH oligodeoxynucleotides significantly inhibited AAH expression and motility in cholangiocarcinoma cells.
|
12713872 |
2003 |
|
Cholangiocarcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
We found that HAAH gene expression was undetectable during bile duct proliferation in both human disease and rat models as compared with cholangiocarcinoma.
|
10728685 |
2000 |
|
Cholangiocarcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma.
|
8823296 |
1996 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
ASPH is silenced in normal adult breast, upregulated from in situ malignancies to highly expressed in invasive/advanced ductal carcinoma.
|
31694640 |
2019 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Small molecule inhibitors (SMIs) of ASPH's β-hydroxylase specifically/efficiently abrogated in vitro metastasis, which mimics basement membrane invasion at primary site, intravasation/extravasation (transendothelial migration), and colonization/outgrowth at distant sites.
|
31694640 |
2019 |